3 Growth Companies With Insider Ownership As High As 32%

In a week marked by mixed performances across major global indices, growth stocks have notably outpaced their value counterparts, driven by strong gains in sectors like consumer discretionary and information technology. Amidst this backdrop, insider ownership can be a compelling factor for investors seeking alignment between company leadership and shareholder interests. As we explore three growth companies with insider ownership as high as 32%, it's crucial to consider how such alignment might influence performance in the current market environment.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
SKS Technologies Group (ASX:SKS)	27%	24.8%
Kirloskar Pneumatic (BSE:505283)	30.3%	26.3%
Seojin SystemLtd (KOSDAQ:A178320)	30.9%	39.9%
Archean Chemical Industries (NSEI:ACI)	22.9%	41.3%
Laopu Gold (SEHK:6181)	36.4%	34.2%
Medley (TSE:4480)	34%	31.7%
Fine M-TecLTD (KOSDAQ:A441270)	17.2%	131.1%
HANA Micron (KOSDAQ:A067310)	18.4%	110.9%
Brightstar Resources (ASX:BTR)	16.2%	84.6%
Findi (ASX:FND)	34.8%	112.9%

Click here to see the full list of 1516 stocks from our Fast Growing Companies With High Insider Ownership screener.

Underneath we present a selection of stocks filtered out by our screen.

EmbedWay Technologies (Shanghai) (SHSE:603496)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: EmbedWay Technologies (Shanghai) Corporation is a Chinese company specializing in network visibility infrastructure and intelligent system platforms, with a market cap of CN¥8.29 billion.

Operations: The company generates revenue from its operations in the computer, communication, and other electronic equipment manufacturing segment, amounting to CN¥1.15 billion.

Insider Ownership: 32.1%

EmbedWay Technologies (Shanghai) demonstrates strong growth potential, with earnings expected to grow significantly at 33.9% per year over the next three years, outpacing the Chinese market's average. The company reported substantial revenue growth for the first nine months of 2024, reaching CNY 880.94 million from CNY 498.37 million a year prior. Despite a high price-to-earnings ratio of 66.8x, it's below industry averages and no recent insider trading activity is noted.

• Click here and access our complete growth analysis report to understand the dynamics of EmbedWay Technologies (Shanghai).
• In light of our recent valuation report, it seems possible that EmbedWay Technologies (Shanghai) is trading beyond its estimated value.

Jianzhijia Pharmaceutical Chain Group (SHSE:605266)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Jianzhijia Pharmaceutical Chain Group Co., Ltd. operates a network of retail pharmacies in China, with a market cap of CN¥4.19 billion.

Operations: Jianzhijia Pharmaceutical Chain Group Co., Ltd. generates its revenue primarily through its network of retail pharmacies in China.

Insider Ownership: 32.9%

Jianzhijia Pharmaceutical Chain Group shows promising growth prospects, with earnings forecasted to grow significantly at 35.8% annually over the next three years, surpassing the Chinese market average. The company trades at a favorable price-to-earnings ratio of 17.7x, below the market's 37.6x. Despite lower profit margins and high debt levels, it announced a share buyback program worth up to CNY 100 million to enhance shareholder value and maintain company stability.

• Click here to discover the nuances of Jianzhijia Pharmaceutical Chain Group with our detailed analytical future growth report.
• Insights from our recent valuation report point to the potential undervaluation of Jianzhijia Pharmaceutical Chain Group shares in the market.

Guangzhou Wondfo BiotechLtd (SZSE:300482)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Guangzhou Wondfo Biotech Co., Ltd is an in vitro diagnostics company specializing in the R&D, production, and sale of point-of-care testing products and rapid diagnosis and chronic disease management solutions in China, with a market cap of CN¥11.86 billion.

Operations: The company's revenue is primarily derived from its Diagnostic Kits and Equipment segment, totaling CN¥2.94 billion.

Insider Ownership: 31.1%

Guangzhou Wondfo Biotech Ltd. demonstrates strong growth potential, with earnings projected to rise by 27.48% annually, outpacing the Chinese market's average. Revenue is also expected to grow significantly at 21.1% per year. Despite recent shareholder dilution, the company trades at a competitive price-to-earnings ratio of 22.6x, below the market average of 37.6x, indicating good relative value compared to peers and industry standards.

• Dive into the specifics of Guangzhou Wondfo BiotechLtd here with our thorough growth forecast report.
• The analysis detailed in our Guangzhou Wondfo BiotechLtd valuation report hints at an deflated share price compared to its estimated value.

Where To Now?

• Get an in-depth perspective on all 1516 Fast Growing Companies With High Insider Ownership by using our screener here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com